drugset / Trial / NCT00795145
A Study To Assess The Effect Of Linezolid On QTc Interval
RandomizedCrossoverTriple-blindBasic science
Summary
The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG readings) which could predispose patients to ventricular arrhythmias. This study is conducted to satisfy this requirement.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linezolid | Other / unclassified | 600 mg | Intravenous |
| Subject | Linezolid | Other / unclassified | 900 mg | Intravenous |
| Subject | Linezolid | Other / unclassified | 1200 mg | Intravenous |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |